Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions

J Am Acad Dermatol. 2000 May;42(5 Pt 1):829-30. doi: 10.1067/mjd.2000.105948.


We treated a 57-year-old woman for refractory inflammatory bowel disease with a humanized anti-tumor necrosis factor alpha monoclonal antibody (Infliximab). The patient also had a 15-year history of Crohn's disease and a 20-year history of moderate to severe psoriasis. She received a single infusion of Infliximab (5 mg/kg). Two weeks after the infusion her psoriasis had dramatically improved in appearance. To our knowledge, our case is the first reported instance of successful anti-tumor necrosis factor alpha therapy in psoriasis.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Crohn Disease / complications
  • Crohn Disease / therapy
  • Dermatologic Agents / therapeutic use*
  • Female
  • Humans
  • Infliximab
  • Middle Aged
  • Psoriasis / complications
  • Psoriasis / pathology
  • Psoriasis / therapy*
  • Tumor Necrosis Factor-alpha / immunology*


  • Antibodies, Monoclonal
  • Dermatologic Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab